A Phase 2 interventional study of CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) and Placebo to match CK-4021586 in Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by Cytokinetics. Recruiting at 26 sites in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Heart Failure by Cytokinetics — 2 open to participants now, 2 under way, 1 of them phase 3. Heart Failure · Cytokinetics.
Among the 15 studies in Heart Failure by Cytokinetics, this one is the 7th largest by planned enrollment, is the only one that started in 2025, is one of 8 in phase 2, and was the 15th registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →2 of the 15 studies in Heart Failure by Cytokinetics are open now, in 10 countries. Recruiting first, the newest first:
Cytokinetics · Sites in United States, Canada, China and 7 more countries
Ages 18–85
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 60 is below the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Median enrollment 50 across the 15 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
1 of the studies in Heart Failure by Cytokinetics that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Heart Failure by Cytokinetics, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants may receive 150 mg or 300 mg of CK-4021586 daily, guided by echocardiography assessments, for 12 weeks total.
Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
Participants will receive placebo daily for up to 12 weeks.
Drug: Placebo to match CK-4021586
Participants may receive 300 mg or 450 mg of CK-4021586 daily, guided by echocardiography assessments, for 12 weeks total.
Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
Participants will receive placebo daily for up to 12 weeks.
Drug: Placebo to match CK-4021586
Participants may receive 450 mg or 600 mg of CK-4021586 daily, guided by echocardiography assessments, for 12 weeks total.
Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
Participants will receive placebo daily for up to 12 weeks.
Drug: Placebo to match CK-4021586
CK-4021586 administered orally
Also known as: ulacamten
Placebo administered orally
Incidence of early drug discontinuation
Incidence of early drug discontinuation observed during dosing of CK 4021586 in patients with HFpEF
Time frame: 12 weeks
Incidence of LVEF < 40%
Incidence of left-ventricular ejection fraction (LVEF) \< 40% observed during dosing of CK-4021586 in patients with HFpEF
Time frame: 12 weeks
Incidence of AEs
Incidence of adverse events observed during dosing of CK-4021586 in patients with HFpEF
Time frame: 12 weeks
Change in NT-proBNP
Change from baseline values in NT-proBNP to Week 6 and Week 12
Time frame: Baseline to Week 6 and Week 12
Plasma concentrations of CK-4021586
Observed 2-hour post dose plasma concentration (C2hr) and minimum plasma concentration (Cmin) for CK-4021586 over the dosing interval
Time frame: 12 weeks
Concentration-response relationship of CK-4021586 on NT-proBNP change
Slope of the relationship of plasma concentration of CK-4021586 to the change from baseline in the NT-proBNP
Time frame: Baseline to Week 12
Concentration-response relationship of CK-4021586 to LVEF change
Slope of the relationship of plasma concentration of CK-4021586 to the change from baseline in the LVEF
Time frame: Baseline to Week 12
Change in LVEF
Change from baseline in LVEF at Week 6 and Week 12
Time frame: Baseline to Week 6 and Week 12
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Sep 2026, 19 months after the start.
Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 19 months is close to that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.